Information Provided By:
Fly News Breaks for January 24, 2019
NBIX
Jan 24, 2019 | 07:32 EDT
Needham analyst Alan Carr downgraded Neurocrine to Hold, saying that the stock looks "fairly valued". The analyst acknowledges that the launch of Ingrezza in Tardive Dyskinesia has been impressive, but contends that since the management reflected on its likely lack of efficacy in Tourette Syndrome, the program's long-term success is "already reflected" in the shares.
News For NBIX From the Last 2 Days
NBIX
NBIX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.